Mexio[®] Eye Drops

Lomefloxacin 0.3% Sterile solution

Lomefloxacin, a difluorinated guinolone derivative, is a bacterial gyrase inhibitor, effective against gram positive and gram negative bacteria. The acute toxicity of Lomefloxacin following systemic and topical ophthalmic application is low. Lomefloxacin interferes with bacterial DNA related processes like initiation, elongation, and termination phases of replication, transcription, DNA repairing, recombination, transposition, supercoiling and relaxation of DNA. The target molecule for guinolones is the A-subunit of bacterial enzyme gyrase (topoisomerase II).

Sensitive germs

Gram-positive: Staphylococcus epidermidis, S. aureus. Bacillus. Corynebacterium.

Gram-negative: Branhamella catarrhalis, Neisseria spp., Acinetobacter spp., Alcaligenes faecalis, Enterobacter spp., Flavobacterium spp., Haemophilus influenzae, Klebsiella, Moraxella, Proteus, Pseudomonas aeruginosa. Pseudomonas spp., Serratia spp.

Anaerobic germs: Propionibacterium acnes.

COMPOSITION

MexIo® 0.3% Eye Drops : Each ml contains Lomefloxacin 3 mg (as Lomefloxacin hydrochloride INN 3.31 mg).

INDICATION

Bacterial infections, including conjunctivitis, blepharitis, blepharoconjunctivitis which are due to Lomefloxacin susceptible germs and Staphylococcus aureus induced corneal ulcers.

DOSAGE AND ADMINISTRATION

Adults and children (above 1 year of age): Insert 1 drop 2-3 times daily into the lower conjunctival sac. At the beginning of the treatment, applications should be more frequent, apply 5 drops within 20 minutes or 1 drop every hour during 6-10 hours.

Duration of the treatment: 7 to 9 days.

CONTRAINDICATION

Hypersensitivity to the active ingredient, to excipients, or to guinolones.

PRECAUTION

Long term treatment with antibiotics may enhance development of secondary fungal infections or may support growth of non susceptible bacteria. Some isolated cases of phototoxicity have been reported after systemic but not after topical ophthalmic use of Lomefloxacin. Nevertheless, during treatment with Lomefloxacin intensive exposure to sunlight or UV-radiation should be avoided.

SIDE EFFECT

Slight and transient burning immediately after instillation of the eve drops has been reported in 4.7% of users. Although phototoxicity has not been reported after ophthalmic use, photosensitization is possible. Since the following allergic reactions have been reported after systemic use of Lomefloxacin, they can not be excluded after topical ophthalmic use: allergic reactions, asthma, dyspnoea, urticaria, erythema, pruritus, and hypersensitization.

DRUG INTERACTION

In order to avoid reduction of efficacy, no ophthalmic preparations containing heavy metals, such as zinc, should be used during 15 minutes preceding and following application of Lomefloxacin.

Bacteriostatic ophthalmic antibiotics should not be used concomitantly with Lomefloxacin eve drops.

USE IN PREGNANCY AND LACTATION

Clinical studies on the use of Lomefloxacin eve drops during human pregnancy or lactation are not available. Therefore, the drug should only be used when the benefit outweighs the potential risk for the foetus or the infant

OVERDOSE

Practically there is no risk of adverse effects due to accidental oral ingestion, since a bottle of 5 ml eye drop solution contains only 15 mg Lomefloxacin. This corresponds to 3.75% of the recommended oral daily dose for adults of 400 mg Lomefloxacin.

STORAGE

Store below 30⁰C in a cool and dry place protected from light. Keep out of reach of children. Do not touch the dropper tip to surfaces since this may contaminate the solution. Do not use after 30 days of first opening.

HOW SUPPLIED

MexIo® 0.3% Eve Drops: Each plastic dropper bottle contains 5 ml of Lomifloxacin 0.3% sterile solution.

Manufactured by



SQUARE PHARMACEUTICALS LTD. BANGLADESH